Welcome to our dedicated page for CHEMED SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Insider sale reported by a company director. The Form 4 shows Patrick P. Grace, a Chemed Corp (CHE) director, sold 150 shares on 09/09/2025 at $463.39 per share. After the sale he directly beneficially owns 3,397 shares. No derivative transactions were reported and the filing is by one reporting person.
Chemed Corporation (CHE) Form 144 disclosure: A notice was filed reporting a proposed sale of 150 shares of the issuer's capital stock through J.P. Morgan Securities LLC on the NYSE, with an approximate sale date of 09/09/2025 and an aggregate market value of 69,567. The shares were acquired on 05/29/2025 as executive compensation from the issuer; the filing shows 277 shares were originally acquired on that date and payment was made on 05/29/2025. The filer reports 14,571,695 shares outstanding for the class. No securities were reported sold by the person in the past three months in this filing.
Joel L. Wherley, listed as an officer (CEO - Vitas Healthcare) of Chemed Corporation (CHE), filed an Initial Form 3 reporting beneficial ownership on 08/27/2025. He directly owns 659 shares of Chemed capital stock and holds stock options exercisable in 2028 and 2029 covering 6,961 and 8,382 shares at exercise prices of $509.46 and $597.70. He also holds multiple performance stock units that convert to shares if performance targets are met over 2023–2027 performance periods.
Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.
Chemed Corp. (CHE) Form 4 filing: Director George J. Walsh III purchased 200 shares of Chemed common stock on 08/04/2025 at $417.10 per share, an outlay of roughly $83,420. His direct holdings rise to 3,523 shares; he also reports 434 shares held indirectly by his spouse. No shares were sold and no derivative positions were opened or closed. The transaction modestly increases the director’s exposure—about a 6% lift in his direct stake—while leaving total company share count essentially unaffected. Insider buying by a non-executive director is often interpreted as a vote of confidence, though the amount is immaterial compared to Chemed’s ~15 million shares outstanding.